Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PKAI as a potential target for therapeutic intervention.

K Taskén1, V Hansson, P Aukrust

  • 1Institute of Medical Biochemistry, University of Oslo, Blindern, Oslo, Norway.

Drug News & Perspectives
|August 26, 2003
PubMed
Summary

We identified a molecular mechanism involving Protein Kinase A type I (PKAI) that impairs T-cell function in HIV and CVI. Blocking PKAI activity significantly improves T-cell immune responses in these patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SmartAPPetite For Youth: pilot and feasibility study of an adolescent smartphone nutrition intervention.

Pilot and feasibility studies·2026
Same author

Elevated KRAS protein level is associated with better survival in pancreatic cancer.

BMC cancer·2025
Same author

The effect of fish oil rich in cetoleic acid on the omega-3 index and skin quality.

Prostaglandins, leukotrienes, and essential fatty acids·2024
Same author

Ghrelin is related to lower brain reward activation during touch.

Psychophysiology·2023
Same author

Transcriptional profiling reveals monocyte-related macrophages phenotypically resembling DC in human intestine.

Mucosal immunology·2018
Same author

Factors Affecting Resident Satisfaction in Continuity Clinic-a Systematic Review.

Journal of general internal medicine·2018

Area of Science:

  • Immunology
  • Molecular Biology
  • Virology

Background:

  • T-cell dysfunction is a hallmark of HIV infection and common variable immunodeficiency (CVI).
  • Protein Kinase A type I (PKAI) is a key inhibitor of immune function in T lymphocytes, activated by antigen receptor triggering.

Purpose of the Study:

  • To elucidate the molecular mechanism of impaired T-cell function in HIV and CVI.
  • To investigate PKAI as a potential therapeutic target for immunodeficiency disorders.

Main Methods:

  • Assessed PKAI activation in T cells from patients with HIV and CVI.
  • Utilized selective antagonists to block cAMP action through PKAI.
  • Administered combination therapy with cAMP antagonists and interleukin-2.
  • Conducted in vitro experiments to evaluate T-cell dysfunction in CVI patients.

Related Experiment Videos

Main Results:

  • T cells from HIV-infected and CVI patients exhibit increased PKAI activation, inhibiting immune function and proliferation.
  • Selective PKAI antagonists improved T-cell function in HIV patients by up to 300%.
  • Combination therapy normalized immune responses and boosted T-cell function in HIV patients by up to 600%.
  • Approximately 50% of CVI patients showed T-cell dysfunction potentially responsive to PKAI-targeted treatment.

Conclusions:

  • PKAI hyperactivation is a key mechanism underlying T-cell impairment in HIV and CVI.
  • Targeting PKAI with selective antagonists represents a promising immunomodulatory therapeutic strategy.
  • This approach holds potential for treating HIV-associated immunodeficiency and other disorders like CVI.